It has been shown that some inhibitors targeting GD3S such as TPL and BMS-345541 downregulated the expression of GD3S via suppression of the NF-κB signaling pathway, which inhibited the malignant characteristics of tumor cells. The gene discussed is NFKB1; the disease is neoplasm.